Spero Therapeutics Inc
SPRO2.530USD
+0.030+1.20%
시장 운영 시간 （ET）시세는 15분 지연됩니다
141.43M시가총액
손실P/E TTM
자세한 내용은 Spero Therapeutics Inc 회사
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
회사 정보
회사 코드SPRO
회사 이름Spero Therapeutics Inc
상장일Nov 02, 2017
설립일2013
CEOMs. Esther Rajavelu
직원 수32
유형Ordinary Share
회계 연도 종료Nov 02
주소675 Massachusetts Ave Ste 14
도시CAMBRIDGE
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호02139-3309
전화18572421600
웹사이트https://sperotherapeutics.com/
회사 코드SPRO
상장일Nov 02, 2017
설립일2013
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
350.79K
+112.94%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
228.68K
+423.52%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
147.00K
-45.80%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
71.45K
+38.87%
Ms. Kathleen Tregoning
Ms. Kathleen Tregoning
Independent Director
Independent Director
55.00K
+57.14%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
55.00K
+57.14%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
55.00K
+57.14%
Mr. Scott T. Jackson
Mr. Scott T. Jackson
Independent Director
Independent Director
--
--
Dr. Patrick Volkert Jo Vink, M.D.
Dr. Patrick Volkert Jo Vink, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. John C. Pottage, Jr., M.D.
Dr. John C. Pottage, Jr., M.D.
Independent Director
Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
350.79K
+112.94%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
228.68K
+423.52%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
147.00K
-45.80%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
71.45K
+38.87%
Ms. Kathleen Tregoning
Ms. Kathleen Tregoning
Independent Director
Independent Director
55.00K
+57.14%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
55.00K
+57.14%
수익 분석
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
데이터 없음
지역별USD
이름
수익
비율
United States
47.98M
0.00%
사업별
지역별
데이터 없음
주주
업데이트 시간: Fri, May 16
업데이트 시간: Fri, May 16
주주 통계
유형
주주 통계
주주
비율
GSK plc
16.44%
Anson Funds Management LP.
6.79%
Pfizer Inc
4.23%
The Vanguard Group, Inc.
3.15%
Renaissance Technologies LLC
1.74%
Other
67.65%
주주 통계
주주
비율
GSK plc
16.44%
Anson Funds Management LP.
6.79%
Pfizer Inc
4.23%
The Vanguard Group, Inc.
3.15%
Renaissance Technologies LLC
1.74%
Other
67.65%
유형
주주
비율
Corporation
20.66%
Hedge Fund
10.30%
Investment Advisor/Hedge Fund
8.22%
Individual Investor
3.66%
Venture Capital
2.58%
Investment Advisor
2.01%
Research Firm
0.14%
Other
52.43%
기관 주식 보유
업데이트 시간: Tue, Mar 4
업데이트 시간: Tue, Mar 4
보고 기간
기관 수
보유 주식
비율
변동
2025Q1
114
27.91M
50.02%
+3.00M
2024Q4
125
27.51M
50.50%
+2.91M
2024Q3
143
24.19M
44.62%
-8.19M
2024Q2
160
25.74M
47.53%
-7.31M
2024Q1
203
25.36M
47.08%
-8.60M
2023Q4
209
24.88M
47.35%
-1.62M
2023Q3
223
24.62M
47.01%
-2.06M
2023Q2
230
24.99M
47.83%
-1.96M
2023Q1
242
24.74M
47.38%
-2.46M
2022Q4
247
26.52M
54.04%
-1.18M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
GSK plc
9.19M
16.44%
--
--
Mar 27, 2025
Anson Funds Management LP.
3.84M
6.87%
+89.44K
+2.38%
Dec 31, 2024
Pfizer Inc
2.36M
4.23%
+2.36M
--
Dec 31, 2024
The Vanguard Group, Inc.
1.76M
3.15%
--
--
Dec 31, 2024
Renaissance Technologies LLC
1.11M
1.98%
+130.94K
+13.43%
Dec 31, 2024
Alphabet, Inc.
889.98K
1.59%
--
--
Dec 31, 2024
Murchinson Ltd.
873.91K
1.56%
+873.91K
--
Dec 31, 2024
Acadian Asset Management LLC
1.04M
1.86%
-31.94K
-2.98%
Dec 31, 2024
Adar1 Capital Management LLC
801.28K
1.43%
+57.82K
+7.78%
Dec 31, 2024
Hamed (Kamal)
788.12K
1.41%
+211.66K
+36.72%
Feb 02, 2024
더 보기
관련 ETF
업데이트 시간: Fri, Jun 6
업데이트 시간: Fri, Jun 6
이름
비율
iShares Micro-Cap ETF
0.01%
iShares Core S&P Total U.S. Stock Market ETF
0%
Avantis US Small Cap Equity ETF
0%
Royce Quant Small-Cap Quality Value ETF
0%
iShares Micro-Cap ETF
비율0.01%
iShares Core S&P Total U.S. Stock Market ETF
비율0%
Avantis US Small Cap Equity ETF
비율0%
Royce Quant Small-Cap Quality Value ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
